CARE is a collaborative effort against HIV/TB/HCV across the European region with a specific focus on the Russian Federation. It capitalises on already established European cohort networks and exploits extensive and longitudinal data and sample sets, both existing and prospectively collected.
The specific research objectives of CARE are to:
Discover and validate novel soluble biomarkers reliably enabling the identification of treatment success of multidrug-resistant tuberculosis (MDR-TB) patients and to diagnose pulmonary tuberculosis.
Explore mechanisms explaining the susceptibility to develop extrapulmonary tuberculosis related to variants of the host gene SIGLEC1 that are also involved in response to HIV infection.
Analyse the correlation between drug-related variants in the tuberculosis genome and corresponding in-vitro drug susceptibility to develop a decision-making support tool for the choice of second line therapy in case of suspected MDR-TB.